Bayer Healthcare LLC

Bayer Intellectual Property Gmbh

Bayer Pharma Aktiengesellschaft

Peter Scholz

Jan Tebbe

Christian Votsmeier

Susanne Steinig

Zhuozhi Wang

Nina Wobst

Joerg Birkenfeld

Junliang Pan

Simone Brückner

Uwe Gritzan

Michael Strerath

Wayne Coco

Ulrich Haupts

Andreas Scheidig

Kerstin Baral

Kornelia Kirchner

Klaus Pellengahr

Hanna Plittersdorf

Joanna Grudzinska

Simone Brueckner

Joanna Grudzinska-Goebel

Jörg Birkenfeld

Wayne M Coco

Jan Tebe

Simone BRÜCKNER

Isolated monoclonal antibodies that bind human tissue factor pathway inhibitor (TFPI) are provided. Isolated nucleic acid molecules encoding monoclonal antibodies that bind TFPI are also contemplated. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treating deficiencies or defects in coagulation by administration of the antibodies are also provided. Methods of producing the antibodies are also provided.

Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)

Provided herein are antibodies, antigen binding portions, and derivatives thereof that are capable of binding tumor necrosis factor alpha (TNF&#x3b1;); nucleic acids encoding the antibodies, antigen binding portions, and derivatives thereof, including complementary nucleic acids; vectors; and host cells containing the nucleic acids.

Antibodies to TNF&#x3b1;

Growing community of inventors

Kleve, Germany

Peter Scholz